DNA-Based Therapy Development for Pancreatic Cancer

DNA-based gene therapy offers promising potential in pancreatic cancer therapies by enabling precise genetic modifications to target cancer cells. Alfa Cytology is dedicated to providing DNA-based therapy development services aimed at advancing innovative treatments for pancreatic cancer by harnessing the power of gene editing technology to correct genetic mutations, restore normal cellular function, and inhibit tumor growth.

Overview of DNA-Based Therapy

In DNA-based gene therapy, the first step involves identifying the specific gene that is causing a genetic disorder or disease. Once the target gene is identified, a healthy copy of the gene is inserted into a vector, which is typically a harmless virus that can efficiently deliver the gene to the target cells. The vector is then introduced into the patient's body through various methods such as injection, inhalation, or direct injection into the affected tissue.

Fig. 1 Manufacturing of DNA-based therapies. (Sussman C, et al, 2024)

Once the vector carrying the healthy gene reaches the target cells, the gene is integrated into the cell's DNA and is able to produce the normal protein that is missing or defective in the patient. This restored function can correct the underlying cause of the disease and potentially lead to significant improvements in the patient's condition.

DNA-Based Therapy Development for Pancreatic Cancer

Gene therapy can be used to target specific genetic mutations that drive pancreatic cancer development, such as mutations in the KRAS, TP53, and SMAD4 genes. Several strategies for DNA-based therapy in pancreatic cancer are currently under development.

• One approach is to deliver tumor-suppressor genes, such as p53 or p16, to restore normal cell growth control and induce apoptosis in cancer cells.
• Another approach is to deliver genes encoding for anti-cancer proteins, such as cytokines or immune checkpoint inhibitors, to stimulate the immune system's response against the tumor.

Our Services

Alfa Cytology offers comprehensive DNA-based therapy development services for pancreatic cancer, encompassing all stages from conceptualization to preclinical validation. Our services include the design and optimization of gene constructs, the development of efficient delivery vectors, and in vitro and in vivo testing. This one-stop solution ensures seamless integration of various processes, facilitating the rapid advancement of gene therapy candidates.

DNA-Based Therapy Type We Develop

DNA Vector Construction Service

DNA vector construction involves several sophisticated techniques to ensure the accurate insertion of therapeutic genes into vectors and the generation of high-quality viral or non-viral vectors for gene delivery.

Vector Systems Selection

This involves evaluating various vectors to determine the most suitable one based on factors such as transduction efficiency, tissue specificity, duration of gene expression, and immunogenicity. Available vector types include the following.

DNA Vector Optimization and Evaluation

This involves combining regulatory elements, promoters, enhancers, and other genetic elements to optimize vector function. We rigorously evaluate vector integrity, stability and transfection efficiency to ensure optimal performance for gene delivery.

Preclinical Testing Service

We offer a comprehensive preclinical testing service, which involves a range of in vitro and in vivo studies designed to thoroughly evaluate the potential of DNA-based gene therapy and any potential risks associated with the therapy.

Why Choose Us?

Through cutting-edge gene editing technology and rigorous preclinical testing, our services are designed to develop innovative therapeutic options that have the potential to transform the treatment of pancreatic cancer. Please do not hesitate to contact us to discuss how our expertise in DNA-based therapy can advance your r esearch and therapeutic goals and pave the way for breakthroughs in cancer treatment.

Reference

1. Sussman C, et al. Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases. Pharmaceutics. 2024, 16(4):535.